We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
French pharma giant Sanofi has unveiled that its multiple myeloma drug isatuximab has met its primary endpoint of prolonged progression-free survival in a Phase III trial.....
The myeloma drug Empliciti is currently approved alongside Revlimid and dexamethasone for patients who have already received anywhere from one to three prior treatments.